Micrometastasis in Gastrointestinal Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01919151|
Recruitment Status : Unknown
Verified August 2013 by Oslo University Hospital.
Recruitment status was: Recruiting
First Posted : August 8, 2013
Last Update Posted : August 12, 2013
Prognostic and predictive value of assessing the patients micrometastasis status in blood and bone marrow when diagnosed GI cancer. 2 different patient subgroups are currently studied, patients with cancer of the pancreas and patients with liver metastasis secondary to colorectal cancer.
Our hypothesis is that patients with detective circulating tumor cells in the blood or disseminated tumour cells in their bone marrow at diagnosis have a more advanced disease than negative patients. This information may be of therapeutic interest.
|Condition or disease|
|Pancreatic Adenocarcinoma Colorectal Cancer|
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||The Process of Metastasis in Colorectal Cancer Tumour Biology and Prognostic Factors in Pancreatic Cancer|
|Study Start Date :||June 2008|
|Estimated Primary Completion Date :||December 2013|
|Estimated Study Completion Date :||December 2015|
Gastrointestinal cancer patients
Patients with radiological suspected cancer in the pancreas Patients with radiological suspected colorectal liver metastasis
- Survival [ Time Frame: 5 year ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01919151
|Contact: Gro Wiedswang, MD,PhDemail@example.com|
|Contact: Evi Faleide, MD,PhD||+4722118080||UXEVAL@us-hf.no|
|Oslo University Hospital||Recruiting|
|Oslo, Norway, 0424|
|Contact: Gro Wiedswang, MD,PhD +47 22119550 firstname.lastname@example.org|
|Principal Investigator: Gro Wiedswang, MD,PhD|
|Study Chair:||Bjørn Atle Bjørnbeth, MD,PhD||Oslo University Hospital, Dep of Gastrointestinal surgery|